Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.

@article{Comella2000OxaliplatinAR,
  title={Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.},
  author={Pasquale Comella and Ferdinando De Vita and Luigi De Lucia and Rossana Casaretti and Antonio Avallone and Michele Orditura and Flavia Rivellini and Sergio Palmeri and G. Catalano and Giuseppe Comella},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2000},
  volume={11 4},
  pages={
          461-8
        }
}
PURPOSE To determine the maximum tolerated dose of oxaliplatin (L-OHP) given as a two-hour infusion followed by raltitrexed (Tomudex [TOM]) administered as a 15-min infusion on day 1, and bolus 5-fluorouracil (5-FU) modulated by a fixed dose of levo-folinic acid (LFA) 250 mg/m2 on day 2, recycling every two weeks, and to have preliminary evidence of activity of this combination in pretreated advanced colorectal cancer patients. PATIENTS AND METHODS Fifty-two patients with advanced colorectal… CONTINUE READING